BusinessFibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)By Nasdaq OMXJan 30, 2018, 1:02 PM UTC
BusinessInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)By Nasdaq OMXJan 24, 2018, 10:31 PM UTC
BusinessFibrocell to Present at Phacilitate Cell and Gene Therapy World 2018By Nasdaq OMXJan 24, 2018, 1:01 PM UTC
BusinessMacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility AnalysisBy Nasdaq OMXJan 23, 2018, 9:30 PM UTC
BusinessAXIM Biotech Announces Successful Completion of Exploratory Meeting with the Dutch Medicines Evaluation Board on MedChew Rx Program for Treatment of Pain and Spasticity in MS PatientsBy Nasdaq OMXJan 23, 2018, 2:02 PM UTC
BusinessSharps Compliance Reports Fiscal 2018 Second Quarter ResultsBy Nasdaq OMXJan 23, 2018, 11:55 AM UTC
BusinessCORRECTION: CEO, Brady Granier, From BioCorRx® Inc. Discusses Upcoming FDA Meeting on “Stock Day” Podcast; Aims to Fight Opioid CrisisBy Nasdaq OMXJan 22, 2018, 3:55 PM UTC
BusinessCEO, Brady Grainer, From BioCorRx®Inc. Paves Pathway Towards Possible FDA Approval on “Stock Day” Podcast; Aims to Fight Opioid CrisisBy Nasdaq OMXJan 22, 2018, 12:00 PM UTC
